Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Blood (2021) 138 (Supplement 1): 695.

https://doi.org/10.1182/blood-2021-145436

Published: 2021

Journal Articles

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results

Junyuan Qi, MD, Jian Li, MD, Bin Jiang, MD, Bo Jiang, MD, Hongzhong Liu, MD, Xinxin Cao, MD, Meixiang Zhang, MD, Yuan Meng, MD, Xiaoyu MA, Yingmin Jia, Jiyuan Guo, Yanni Zhang, Wei Huang, Jianxiang Wang, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134391

Published: 2020

Journal Articles

Dead/H-Box Helicase 11 ( DDX11 ) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice

Blood (2019) 134 (Supplement_1): 2732.

https://doi.org/10.1182/blood-2019-127831

Published: 2019

Journal Articles

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Blood (2019) 134 (Supplement_1): 1421.

https://doi.org/10.1182/blood-2019-127937

Published: 2019

Journal Articles

Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?

Ya-Lan Zhou, MD, Li-Xin Wu, Robert Peter Gale, Run-Qing Lu, Jin-Lan Li, Hao Jiang, Qian Jiang, MD, Bin Jiang, Zi-Long Wang, Ting-Ting He, Yue Wang, Xiao-Xiao Zhang, Xiaohui Zhang, MD, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Guorui Ruan

Blood (2018) 132 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2018-99-116592

Published: 2018

Journal Articles

Determinants of Early Death and Outcomes for Acute Promyelocytic Leukemia in the Arsenic Era: A Real World Study

Honghu Zhu, Jinsong Jia, Jiang Qian, PhD, Hao Jiang, MD, Jin Lu, Bin Jiang, Xiaojun Huang

Blood (2017) 130 (Supplement 1): 1340.

https://doi.org/10.1182/blood.V130.Suppl_1.1340.1340

Published: 2017

Journal Articles

Mutation Topology of Adult B-Cell Acute Lymphoblastic Leukaemia

Li-Xin Wu, Run-Qing Lu, Kai-Yan Liu, Robert Peter Gale, MD ScD, PhD, Qi Zheng, Jiao Zhou, Jin-Lan Li, Shu-Juan Wang, Hao Jiang, MD, Qian Jiang, MD, Bin Jiang, Xiao-Hui Zhang, MD, Lan-Ping Xu, Yue Wang, Cheng-Li Song, Ya-Zhen Qin, Yan-Rong Liu, Xiao-Jun Huang, MD, Guo-Rui Ruan

Blood (2017) 130 (Supplement 1): 3986.

https://doi.org/10.1182/blood.V130.Suppl_1.3986.3986

Published: 2017

Journal Articles

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience

xiao-Jun Huang, MD, Jing Wang, MD, Qian Jiang, MD, Huan Chen, Lanping Xu, Xiao-Hui Zhang, Ya-Zhen Qin, Hao Jiang, MD, Jin Lu, Kai-Yan Liu, Bin Jiang

Blood (2016) 128 (22): 2308.

https://doi.org/10.1182/blood.V128.22.2308.2308

Published: 2016

Journal Articles

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Jun Ma, MD, Ting Liu, MD, Jie Jin, MD PhD, Jianda Hu, MD PhD, Qifa Liu, MD, Jianxiang Wang, MD, Zhixiang Shen, MD, Xin Du, MD PhD, Bin Jiang, MD, Xianhua Meng, PhD

Blood (2016) 128 (22): 5198.

https://doi.org/10.1182/blood.V128.22.5198.5198

Published: 2016

Journal Articles

Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

Jianxiang Wang, MD PhD, Yingchang Mi, MD PhD, Bin Jiang, Xiequn Chen, Chunyan Ji, MD PhD, Yan Li, Xielan Zhao, Yongrong Lai, Yu Hu, MD, PhD, Aiping Tang, Ting Liu, MDPhD, Jie Jin, MD PhD, Junmin Li, Linhua Yang, Jianyong Li, MD PhD, Fanyi Meng

Blood (2015) 126 (23): 220.

https://doi.org/10.1182/blood.V126.23.220.220

Published: 2015

Journal Articles

Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center

Ya-Zhen Qin, Honghu Zhu, Qian Jiang, Hao Jiang, Le-Ping Zhang, Jin-Lan Li, Ling-Di Li, Yan-Rong Liu, Yue-Yun Lai, Hong-Xia Shi, Bin Jiang, MD, Xiao-Jun Huang, MDPhD

Blood (2014) 124 (21): 1000.

https://doi.org/10.1182/blood.V124.21.1000.1000

Published: 2014

Journal Articles

KIT Mutation Versus MRD, Which Is More Important To Predict Relapse Of Acute Myeloid Leukemia With t (8; 21)?

Hong-Hu Zhu, MD, Daihong Liu, Hao Jiang, Ya-Zhen Qin, MS, Lan-Ping Xu, MD, Qian Jiang, Xiao-Hui Zhang, M.D., Ph.D., Huan Chen, Jin Lu, MD, Yu Wang, Li-Ru Wang, MD, Jun-Yue Chai, MM, Kai-Yan Liu, MD, Bin Jiang, MD, Xiao-Jun Huang, MD, PhD

Blood (2013) 122 (21): 1309.

https://doi.org/10.1182/blood.V122.21.1309.1309

Published: 2013

Journal Articles

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

Hao Jiang, Daihong Liu, Lanping Xu, Kaiyan Liu, Shanshan Chen, MD, Bin Jiang, MD, Qian Jiang, Huan Chen, Yuhong Chen, Wei Han, MD, Xiaohui Zhang, Yazhen Qin, Yueyun Lai, Yanrong Liu, MD, PhD, Xiaojun Huang

Blood (2013) 122 (21): 4035.

https://doi.org/10.1182/blood.V122.21.4035.4035

Published: 2013

Journal Articles

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

Blood (2013) 121 (20): 4056–4062.

https://doi.org/10.1182/blood-2012-11-468348

Published: 2013

Includes: Supplemental data

Journal Articles

CD58-Negtive Leukemia Initiating Cells Are Independently Associated with High Risk of Relapse in B-Precursor Acute Lymphoblastic Leukemia: A Comprehensive Clinical and Biological Profiling Study

Yuan Kong, MD, PhD, Yanrong Liu, MD, Honghu Zhu, PhD, Qian Jiang, MD, Hao Jiang, MD, Lan-Ping Xu, MD, Dai-Hong Liu, MD, PhD, Guo-Rui Ruan, PhD, Bin Jiang, MD, Kaiyan Liu, MD, Xiao-jun Huang, MD, PhD

Blood (2012) 120 (21): 1397.

https://doi.org/10.1182/blood.V120.21.1397.1397

Published: 2012

Journal Articles

Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance

Qian Jiang, MD, Ya-Zhen Qin, MS, Yue-Yun Lai, MD, Bin Jiang, MD, Hao Jiang, Hong-Xia Shi, MD, Xiao-Jun Huang, MD

Blood (2012) 120 (21): 3755.

https://doi.org/10.1182/blood.V120.21.3755.3755

Published: 2012

Journal Articles

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

Xiao-Jun Huang, Hong-Hu Zhu, Ying-Jun Chang, Lan-Ping Xu, Dai-Hong Liu, Xiao-Hui Zhang, Bin Jiang, Qian Jiang, Hao Jiang, Yu-Hong Chen, Huan Chen, Wei Han, Kai-Yan Liu, Yu Wang

Blood (2012) 119 (23): 5584–5590.

https://doi.org/10.1182/blood-2011-11-389809

Published: 2012

Includes: Supplemental data

Journal Articles

Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,

Yingjun Chang, Honghu Zhu, Lanping Xu, Hao Jiang, MD, Daihong Liu, Qian Jiang, Kaiyan Liu, MD, PhD, Jin Lu, MD, Bin Jiang, Xiaojun Huang

Blood (2011) 118 (21): 4161.

https://doi.org/10.1182/blood.V118.21.4161.4161

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase

Blood (2011) 118 (21): 162.

https://doi.org/10.1182/blood.V118.21.162.162

Published: 2011

NARROW

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results

Dead/H-Box Helicase 11 ( DDX11 ) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?

Determinants of Early Death and Outcomes for Acute Promyelocytic Leukemia in the Arsenic Era: A Real World Study

Mutation Topology of Adult B-Cell Acute Lymphoblastic Leukaemia

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center

KIT Mutation Versus MRD, Which Is More Important To Predict Relapse Of Acute Myeloid Leukemia With t (8; 21)?

Efficacy Analysis With Imatinib Monotherapy Was Superior To Allogeneic Hematopoietic Stem Transplantation In Pediatric Patients With Chronic Phase Of Chronic Myelogenous Leukemia

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

CD58-Negtive Leukemia Initiating Cells Are Independently Associated with High Risk of Relapse in B-Precursor Acute Lymphoblastic Leukemia: A Comprehensive Clinical and Biological Profiling Study

Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only